Mirati Therapeutics

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Mirati Therapeutics reports successful KRAZATI launch amidst financial challenges

Mirati Therapeutics had a transformative year with the successful launch of KRAZATI for KRAS G12C mutated lung cancer.
Despite a net loss in Q4 2022, the company ended the year with a strong cash position and positive market feedback.
Challenges include financial losses, maximizing target inhibition with PRMT5 inhibitors, and regulatory hurdles for Phase 3 trials.
Opportunities lie in collaborations, combination therapies, Phase 3 trials, and advancing pipeline products for future growth.

Mirati Therapeutics reports strong Q1 performance and advances pipeline

Mirati Therapeutics showcased a strong financial performance in Q1 2023, driven by the successful launch of KRAZATI and progress in clinical studies for MRTX1133. The company's commitment to advancing its pipeline and addressing inquiries from analysts reflects a strategic focus on innovation and stakeholder engagement. Despite facing challenges such as a significant net loss, Mirati remains well-positioned with a robust cash position and promising growth opportunities.

Mirati Therapeutics reports strong Q2 performance and navigates strategic challenges

Mirati Therapeutics showcased strong commercial performance, promising clinical data, and proactive financial management strategies in its Q2 2023 Earnings Call.
While facing challenges in market positioning, trial complexities, and operational management, the company remains well-positioned to capitalize on opportunities in advancing its pipeline and optimizing financial performance.
Analysts' inquiries highlighted key areas of interest and concern, signaling the importance of strategic decision-making, regulatory navigation, and competitive positioning for Mirati's future success.
Overall, Mirati's focus on innovation, patient outcomes, and financial sustainability underscores its commitment to driving therapeutic advancements, addressing unmet medical needs, and delivering long-term value to stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mirati Therapeutics Inc is a Biotechnology company located in 9363 Towne Centre Dr, San Diego, CA, United States.

Shares have risen by over 600% since my initial article but have fallen by 17% since my June update piece.

Mirati Therapeutics: Revisiting As KRAS Data Nears

Mirati stock recently went up, but on news unrelated to its lead drug candidate.

Mirati: Lead Candidate Shows Superiority Over Opdivo In NSCLC

Mirati Therapeutics inks partnership with Novartis to develop a combination treatment for advanced solid tumors that have the KRAS mutation.

Mirati Is The Biotech To Watch As Second Half Catalyst Rapidly Approaches

Mirati (MRTX) inks a clinical collaboration with Novartis to evaluate the combination of the former's MRTX849 and the latter's SHP2 inhibitor, TNO155, in patients with advanced solid tumors.

Mirati Inks Deal with Novartis to Evaluate Tumor Candidate

A collaboration with Swiss pharma giant Novartis could validate an experimental cancer treatment from biotech company Mirati Therapeutics, an analyst said Wednesday as Mirati stock rose.

How This Novartis Mashup Could Validate A Biotech Company's Cancer Drug

The stock has gained 60% during the past month and doubled over the past year.

Mirati Therapeutics Still Has Room To Grow

AbbVie

Biogen

These three biotech stocks should be outstanding long-term growth vehicles.

Three Top Biotech Stocks to Buy Right Now

Exelixis

Pfizer

Around $36 billion worth of biopharma acquisitions over the past few years suggests smaller might be better.

Read This Before You Buy Any New Cancer Drug Stocks

Investors need to pay close attention to Mirati Therapeutics (MRTX) stock based on the movements in the options market lately.

Implied Volatility Surging for Mirati Therapeutics (MRTX) Stock Options

TopBuild

PROS Hlds

These lesser-known mid-cap stocks are posting stronger returns than the majority of widely held plays touted in the financial media.

3 Under-the-Radar Stocks Trading at All-Time Highs

In the IBI Expert Interview back in 2017, I discussed with Decision Analytics about tyrosine kinase inhibitors. And I learned that these drugs were gaining market traction.

Mirati: Brewing A Knockout Combo Against Cancers

Mirati's stock soars on the back of positive results from Amgen's Phase 1 study using AMG 510, because it has a similar drug targeting the same oncogene KRAS known as MRTX849.

Mirati's Stock Gaps Higher On Amgen's Data, Opens Up Massive Opportunity

Shares have risen by over 800% since my original article.

Mirati Therapeutics: Updates To Thesis, ASCO Winner Sans Data

Avalara Inc

Guardant Health Inc

Iovance Biotherapeutics

Spark Therapeutics

Roku

Sinclair Inc

Snap

Roku, Array Biopharma and Guardant Health are just some of the best stocks by returns for the first half of 2019. The post The 10 Best Stocks for 2019 — So Far appeared first on InvestorPlace.

The 10 Best Stocks for 2019 — So Far

Amgen

Mirati Therapeutics Inc (NASDAQ: MRTX)'s shares have been on a tear, advancing over 50 percent since Amgen, Inc.

How Does Mirati's Lung Cancer Candidate Stack Up Against Amgen's?

Gilead Sciences

Success with an experimental new oncology treatment that scratches a 35-year itch is good news for more than one biotech stock.

3 Cancer Stocks Given a Lift by Amgen

Nektar Therapeutics

Biotech stocks jumped Monday after pharmaceutical companies presented some positive drug trial results on experimental medicines that give hope for breakthrough treatments for a number of the world's toughest cancers.

Biotech stocks jump after drugmakers show positive data for potential breakthrough cancer treatments

It looks like a target considered undruggable is actually within reach.

Here's Why Mirati Therapeutics Is Jumping Today

Agios Pharmaceuticals

MacroGenics

The 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) is scheduled for May 31 to June 4 in Chicago.

Thursday’s Top 4 ASCO Movers

Options Traders Expect Huge Moves in Mirati Therapeutics (MRTX) Stock

News for Mirati Therapeutics Stock (MRTX)